| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10908924 | Leukemia Research | 2014 | 5 Pages |
Abstract
Erlotinib appears to induce a significant number of responses in higher risk MDS/AML having failed AZA treatment. Given the good safety profile of Erlotinib, its combination with other drugs could be tested in the future in MDS and AML.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sylvain Thepot, Simone Boehrer, Valérie Seegers, Thomas Prebet, Odile Beyne-Rauzy, Eric Wattel, Jacques Delaunay, Emmanuel Raffoux, Mathilde Hunault, Eric Jourdan, Fatiha Chermat, Marie Sebert, Guido Kroemer, Pierre Fenaux, Lionel Adès,